Could Alcon (ALC) and RxSight (RXST)’s Partnership Reshape the Future of Cataract Surgery?
Two ophthalmic technology leaders, Alcon Inc. (NYSE:ALC) and RxSight, Inc.
Rxsight Inc. (RXST)
Market is closed
Sector: Ophthalmic Goods
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Millennium Management Israel Englander | 3,030,287 | $14,605,983 | +48% | 0.01% |
| 2. | No Street Capital Jeff Osher | 2,055,000 | $9,905,100 | +3% | 0.6% |
| 3. | D E Shaw D. E. Shaw | 1,985,215 | $9,568,737 | +2% | 0% |
| 4. | AQR Capital Management Cliff Asness | 1,533,826 | $7,393,041 | +142% | 0% |
| 5. | Marshall Wace LLP Paul Marshall And Ian Wace | 995,916 | $4,800,316 | +7727% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $31.13 | 1,767 | $55,004.24 | 3,210 | 2025-01-16 | Filing | |
| $31.19 | 1,443 | $44,999.96 | 1,443 | 2025-01-15 | Filing | |
| $44.50 | 1,705 | $75,872.50 | 38,438 | 2024-11-13 | Filing | |
| $44.98 | 4,090 | $183,968.20 | 36,733 | 2024-11-13 | Filing | |
| $45.00 | 5,570 | $250,650.00 | 474,141 | 2024-11-13 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $6.96 | 5,100 | $35,496.00 | 71,775 | 2026-09-02 | Filing | |
| $6.96 | 7,765 | $54,044.40 | 25,049 | 2026-09-02 | Filing | |
| $6.96 | 2,041 | $14,205.36 | 81,509 | 2026-09-02 | Filing | |
| $6.96 | 2,041 | $14,205.36 | 200,348 | 2026-09-02 | Filing | |
| $25.71 | 7,000 | $180,001.50 | 24,793 | 2025-03-12 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 5,790,408 | $27,909,765 | 0% | |
| 2. | 2,000,060 | $9,640,289 | 0.01% | |
| 3. | 1,675,582 | $8,076,305 | 0% | |
| 4. | 1,201,195 | $5,789,760 | 0.01% | |
| 5. | 1,131,400 | $5,453,348 | 0.01% |
News See All
RxSight, Inc. (NASDAQ:RXST) Q1 2026 Earnings Call Transcript
RxSight, Inc. (NASDAQ:RXST) Q1 2026 Earnings Call Transcript May 9, 2026 Operator: Hello, everyone. Thank you for joining us, and welcome to the RxSight First Quarter 2026 Earnings Conference Call.
RxSight, Inc. (NASDAQ:RXST) Q4 2025 Earnings Call Transcript
RxSight, Inc. (NASDAQ:RXST) Q4 2025 Earnings Call Transcript February 25, 2026RxSight, Inc. beats earnings expectations. Reported EPS is $-0.22224, expectations were $-0.23.
RxSight, Inc. (RXST) Initiated at Market Perform as Firm Seeks Sales Reacceleration
We recently published an article titled 10 Best Long Term Healthcare Stocks to Buy. On January 30, William Blair initiated coverage of RxSight, Inc.
10 Best Long Term Healthcare Stocks to Buy
In this article, we will discuss 10 Best Long Term Healthcare Stocks to Buy.
RxSight, Inc. (NASDAQ:RXST) Q3 2025 Earnings Call Transcript
RxSight, Inc. (NASDAQ:RXST) Q3 2025 Earnings Call Transcript November 5, 2025RxSight, Inc. misses on earnings expectations. Reported EPS is $-0.24 EPS, expectations were $-0.19.
RxSight (RXST) Fell Due to Missed Expectations and Guidance Reduction
Brown Capital Management, an investment management company, released its “The Brown Capital Management Small Company Fund” second quarter 2025 investor letter.
RxSight, Inc. (NASDAQ:RXST) Q2 2025 Earnings Call Transcript
RxSight, Inc. (NASDAQ:RXST) Q2 2025 Earnings Call Transcript August 8, 2025 Operator: Ladies and gentlemen, thank you for standing by. My name is Desiree, and I will be your conference operator today.
Wells Fargo Upgrades RxSight (RXST), Sees LAL Technology as Undervalued
Wells Fargo upgraded RxSight Inc. (NASDAQ:RXST) from Equal Weight to Overweight on Monday, while raising its price target from $17 to $25 due to an attractive valuation at the current stock price.
RxSight, Inc. (NASDAQ:RXST) Q4 2024 Earnings Call Transcript
RxSight, Inc. (NASDAQ:RXST) Q4 2024 Earnings Call Transcript February 25, 2025RxSight, Inc. misses on earnings expectations. Reported EPS is $0.03 EPS, expectations were $0.1.
Hedge Fund Resource Center